7.11
-0.16(-2.20%)
Currency In USD
Address
5858 Horton Street
EmeryVille, CA 94608
United States of America
Phone
510 505 2680
Sector
Healthcare
Industry
Biotechnology
Employees
227
First IPO Date
December 11, 2020
| Name | Title | Pay | Year Born |
| Dr. David H. Kirn M.D. | Co-Founder, Chief Executive Officer & Director | 1.01M | 1963 |
| Dr. John F. Milligan Ph.D. | Executive Chairman | 150,000 | 1961 |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Officer | 201,288 | 1963 |
| Ms. Theresa Janke | Co-Founder & Chief of Staff | 652,315 | 1975 |
| Dr. Robert Y. Kim M.B.A., M.D. | Chief Medical Officer | 704,843 | 1961 |
| Dr. Fariborz Kamal Ph.D. | President & Chief Operating Officer | 734,607 | 1963 |
| Mr. Uneek Mehra | Chief Financial & Business Officer | 823,899 | 1973 |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 0 | 1972 |
| Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. | Senior Vice President & Therapeutic Area Head of Pulmonology | 0 | 1961 |
| Dr. An Song Ph.D. | Chief Development Officer | 0 | N/A |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
